Theranostics 2020; 10(11):4900-4902. doi:10.7150/thno.44568 This issue

Editorial

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy

Finn Edler von Eyben1✉, Harshad R. Kulkarni2, Richard P. Baum2

1. Center of Tobacco Control Research, Odense, Denmark;
2. Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
von Eyben FE, Kulkarni HR, Baum RP. Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy. Theranostics 2020; 10(11):4900-4902. doi:10.7150/thno.44568. Available from https://www.thno.org/v10p4900.htm

File import instruction

Abstract

Graphic abstract

PSMA based radioligand is a new investigational drug for treatment of metastatic multidrug-resistant and castration-resistant prostate cancer. Prognostic factors point to above and below average overall survival (OS) after the treatment.

Kessel et al. [Theranostics 2019;9:4841-8] reported for the first time that two sites of visceral metastases, lungs and liver, differed in impact on OS after treatment with 177Lu PSMA 617. Treatment with established drugs showed the same trend. The difference in OS between the sites is independent of the type of treatment and can reflect changes in tumor biology during the progression of metastatic prostate cancer.

Keywords: prostate specific membrane antigen, 177Lutetium [177Lu]-PSMA radioligand therapy, prostatic neoplasms, restaging, overall survival